Biocon Limited (BIOCON) reported its Q2 FY27 results, showing a 2% increase in revenue to ₹4,423 Cr compared to ₹4,389 Cr in the same period last year. The company’s EBITDA margin, however, declined to 20% from 22% in Q2 FY26. The focus remains on translating growth into improved margins, free cash flow, debt reduction, and higher returns on capital.

Biosimilars Performance

The Biosimilars segment recorded revenue of ₹2,809 Cr, up 3% YoY. EBITDA stood at ₹623 Cr with a 22% margin. The segment’s performance was impacted by the timing of revenue recognition on certain shipments. The 10-year Pertuzumab partnership in Brazil provides long-term revenue visibility.

Generics Segment

The Generics segment saw a 10% YoY revenue growth to ₹774 Cr. EBITDA margin expanded by over 700bps YoY to 8%. Liraglutide is gaining traction across markets, strengthening the complex injectables portfolio.

Services Division

The Services division revenue stood at ₹833 Cr, up 13% QoQ. EBITDA margin improved by 500bps QoQ to 20%. The division expects further improvement in the second half of the fiscal year.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Biocon Limited (NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal second quarter ended September 30, 2026. The company reported total income of Rs 4,423 crore, up 1% year-on-year (YoY). The consolidated operating revenue increased 2% YoY to Rs 4,389 crore.

Financial Performance

Biopharma revenue increased 5% YoY to Rs 3,583 crore. Biosimilars revenue increased 3% YoY to Rs 2,809 crore, while generics revenue increased 10% YoY to Rs 774 crore. Services revenue increased 13% quarter-on-quarter (QoQ) to Rs 833 crore.

Leadership Comments

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, stated, ‘Biocon continued to achieve industry firsts in biosimilars, with our Pertuzumab becoming the first monoclonal antibody biosimilar recommended under the EMA’s new tailored clinical development pathway.’ Shreehas Tambe, CEO & Managing Director, Biocon Limited, added, ‘We are well positioned for growth in the second half of FY27, with the upcoming European launch of Pertuzumab and expanded insulin manufacturing capacity in Malaysia to support growing U.S. demand.’

As a result, Biocon Limited is confident in its long-term growth trajectory, driven by strategic milestones and continued investments in technology and innovation.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Biocon Limited (NSE: BIOCON), an innovation-led global biopharmaceutical company, announced on October 29, 2026, that it has been ranked No. 13 among the Top 20 Global Employers in biotechnology, biopharmaceutical, pharmaceutical, and related industries in the 2026 survey conducted by the prestigious U.S.-based Science magazine. This recognition reflects Biocon’s long-standing reputation as an employer of choice in the global life sciences industry.

Recognition for Social Responsibility

Biocon was recognized for three key attributes: social responsibility, respect for employees, and a culture aligned with employee values. Shreehas Tambe, CEO and Managing Director, Biocon, said: “I am proud that Biocon has been recognized by Science magazine as one of the world’s Top 20 biopharmaceutical employers for the 15th consecutive year. This recognition reflects the talent, passion, and commitment of our people.”

People-Centric Culture

Biocon’s people-centric culture continues to be a key differentiator in strengthening its employer brand globally. Today, employees representing 37 nationalities across more than 60 cities worldwide contribute diverse perspectives and expertise to Biocon’s mission of delivering life-changing medicines to patients around the world.

As Biocon advances its ambition to become a fully integrated global medicines company, it remains committed to fostering a culture of innovation, excellence, and collaboration enabling it to make a meaningful difference to patients worldwide.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.